Abstract
Asthma is a chronic inflammatory disorder of the airways. Schisandrin B (SB) is the main effective component. This study investigated the effects of SB on airway inflammation and airway remodeling in asthma. The rat model of asthma was established. The rats were treated with SB to evaluate the effects of SB on airway inflammation, airway remodeling, NLRP3 inflammasome activation, and pyroptosis. Alveolar macrophages of rats were isolated, and the macrophage inflammatory model was established by lipopolysaccharide (LPS) induction. The LPS-induced macrophages were treated with SB. The binding relationship between miR-135a-5p and TPRC1 was analyzed. LPS + SB-treated macrophages were transfected with miR-135a-5p inhibitor. The expressions of key factors of the STAT3/NF-κB pathway were detected. SB reduced airway inflammation and airway remodeling in asthmatic rats. SB inhibited NLRP3 inflammasome activation and reduced pyroptosis in asthmatic rats and LPS-induced macrophages. SB reversely regulated the miR-135a-5p/TRPC1 axis. Downregulation of miR-135a-5p attenuated the inhibitory effect of SB on NLRP3 inflammasome activation. SB inhibited the STAT3/NF-κB pathway via the miR-135a-5p/TRPC1 axis. In conclusion, SB inhibited NLRP3 inflammasome activation and reduced pyroptosis via the miR-135a-5p/TRPC1/STAT3/NF-κB axis, thus alleviating airway inflammation and airway remodeling in asthma. This study may confer novel insights for the management of asthma.
Similar content being viewed by others
Data Availability
The datasets and materials used and/or analyzed during the current study are available from the corresponding author on reasonable request.
References
Radhakrishna, N., T.R. Tay, F. Hore-Lacy, R. Hoy, E. Dabscheck, and M. Hew. 2016. Profile of difficult to treat asthma patients referred for systematic assessment. Respir Med 117: 166–173.
Bousquet, J., E. Mantzouranis, A.A. Cruz, N. Ait-Khaled, et al. 2010. Uniform definition of asthma severity, control, and exacerbations: Document presented for the World Health Organization Consultation on Severe Asthma. J Allergy Clin Immunol 126 (5): 926–938.
Akinbami, L.J., J.E. Moorman, A.E. Simon, and K.C. Schoendorf. 2014. Trends in racial disparities for asthma outcomes among children 0 to 17 years, 2001-2010. J Allergy Clin Immunol 134 (3): 547–553 e545.
Alhassan, S., Y. Hattab, O. Bajwa, E. Bihler, and A.C. Singh. 2016. Asthma. Crit Care Nurs Q 39 (2): 110–123.
Fergeson, J.E., S.S. Patel, and R.F. Lockey. 2017. Acute asthma, prognosis, and treatment. J Allergy Clin Immunol 139 (2): 438–447.
Mims, J.W. 2015. Asthma: definitions and pathophysiology. Int Forum Allergy Rhinol 5 (Suppl 1): S2–S6.
Papi, A., C. Brightling, S.E. Pedersen, and H.K. Reddel. 2018. Asthma. Lancet 391 (10122): 783–800.
Castillo, J.R., S.P. Peters, and W.W. Busse. 2017. Asthma exacerbations: Pathogenesis, prevention, and treatment. J Allergy Clin Immunol Pract 5 (4): 918–927.
Boulet, L.P. 2018. Airway remodeling in asthma: Update on mechanisms and therapeutic approaches. Curr Opin Pulm Med 24 (1): 56–62.
Liu, G., M.A. Cooley, P.M. Nair, C. Donovan, A.C. Hsu, A.G. Jarnicki, T.J. Haw, N.G. Hansbro, Q. Ge, A.C. Brown, H. Tay, P.S. Foster, P.A. Wark, J.C. Horvat, J.E. Bourke, C.L. Grainge, W.S. Argraves, B.G. Oliver, D.A. Knight, J.K. Burgess, and P.M. Hansbro. 2017. Airway remodelling and inflammation in asthma are dependent on the extracellular matrix protein fibulin-1c. J Pathol 243 (4): 510–523.
Al-Muhsen, S., J.R. Johnson, and Q. Hamid. 2011. Remodeling in asthma. J Allergy Clin Immunol 128 (3): 451–462 quiz 463-454.
Du, H., Y. Wang, Y. Shi, J. Yu, W. Sun, and Y. Zhang. 2016. Effect of traditional Chinese medicine on inflammatory mediators in pediatric asthma. Mediat Inflamm 2016: 5143703.
Rybnikar, M., K. Smejkal, and M. Zemlicka. 2019. Schisandra chinensis and its phytotherapeutical applications. Ceska Slov Farm 68 (3): 95–118.
Nasser, M.I., S. Zhu, C. Chen, M. Zhao, H. Huang, and P. Zhu. 2020. A Comprehensive review on Schisandrin B and its biological properties. Oxidative Med Cell Longev 2020: 2172740.
Leong, P.K., and K.M. Ko. 2016. Schisandrin B: A double-edged sword in nonalcoholic fatty liver disease. Oxidative Med Cell Longev 2016: 6171658.
Ji, Z.R., W.L. Xue, and L. Zhang. 2019. Schisandrin B attenuates inflammation in LPS-induced sepsis through miR-17-5p downregulating TLR4. Inflammation 42 (2): 731–739.
Mou, Z., Z. Feng, Z. Xu, F. Zhuang, X. Zheng, X. Li, J. Qian, and G. Liang. 2019. Schisandrin B alleviates diabetic nephropathy through suppressing excessive inflammation and oxidative stress. Biochem Biophys Res Commun 508 (1): 243–249.
Zhang, X.Y., L.X. Zhang, Y.L. Guo, L.M. Zhao, X.Y. Tang, C.J. Tian, D.J. Cheng, X.L. Chen, L.J. Ma, and Z.C. Chen. 2016. Schisandrin B inhibits the proliferation of airway smooth muscle cells via microRNA-135a suppressing the expression of transient receptor potential channel 1. Cell Biol Int 40 (7): 742–749.
Zhang, X.Y., X.Y. Tang, L.J. Ma, Y.L. Guo, X.S. Li, L.M. Zhao, C.J. Tian, D.J. Cheng, Z.C. Chen, and L.X. Zhang. 2017. Schisandrin B down-regulated lncRNA BCYRN1 expression of airway smooth muscle cells by improving miR-150 expression to inhibit the proliferation and migration of ASMC in asthmatic rats. Cell Prolif 50 (6): e12382.
Agarwal, V., G.W. Bell, J.W. Nam, and D.P. Bartel. 2015. Predicting effective microRNA target sites in mammalian mRNAs. Elife 4.
Maslan, J., and J.W. Mims. 2014. What is asthma? Pathophysiology, demographics, and health care costs. Otolaryngol Clin N Am 47 (1): 13–22.
Bergeron, C., and L.P. Boulet. 2006. Structural changes in airway diseases: Characteristics, mechanisms, consequences, and pharmacologic modulation. Chest 129 (4): 1068–1087.
Lee, M.Y., C.S. Seo, N.H. Lee, H. Ha, J.A. Lee, H. Lee, K.Y. Lee, and H.K. Shin. 2010. Anti-asthmatic effect of schizandrin on OVA-induced airway inflammation in a murine asthma model. Int Immunopharmacol 10 (11): 1374–1379.
Lee, K.S., S.J. Park, S.R. Kim, K.H. Min, K.Y. Lee, Y.H. Choe, S.H. Hong, Y.R. Lee, J.S. Kim, S.J. Hong, and Y.C. Lee. 2008. Inhibition of VEGF blocks TGF-beta1 production through a PI3K/Akt signalling pathway. Eur Respir J 31 (3): 523–531.
Wang, L., B. Zha, Q. Shen, H. Zou, C. Cheng, H. Wu, and R. Liu. 2018. Sevoflurane inhibits the Th2 response and NLRP3 expression in murine allergic airway inflammation. J Immunol Res 2018: 9021037.
Cheng, Y., S. Li, M. Wang, C. Cheng, and R. Liu. 2018. Peroxisome proliferator activated receptor gamma (PPARgamma) agonist rosiglitazone ameliorate airway inflammation by inhibiting toll-like receptor 2 (TLR2)/Nod-like receptor with pyrin domain containing 3 (NLRP3) inflammatory corpuscle activation in asthmatic mice. Med Sci Monit 24: 9045–9053.
Jorgensen, I., M. Rayamajhi, and E.A. Miao. 2017. Programmed cell death as a defence against infection. Nat Rev Immunol 17 (3): 151–164.
He, W.T., H. Wan, L. Hu, P. Chen, X. Wang, Z. Huang, Z.H. Yang, C.Q. Zhong, and J. Han. 2015. Gasdermin D is an executor of pyroptosis and required for interleukin-1beta secretion. Cell Res 25 (12): 1285–1298.
Zhuang, J., H. Cui, L. Zhuang, Z. Zhai, F. Yang, G. Luo, J. He, H. Zhao, W. Zhao, Y. He, and E. Sun. 2020. Bronchial epithelial pyroptosis promotes airway inflammation in a murine model of toluene diisocyanate-induced asthma. Biomed Pharmacother 125: 109925.
Murray, P.J., and T.A. Wynn. 2011. Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol 11 (11): 723–737.
Lamkanfi, M., and V.M. Dixit. 2014. Mechanisms and functions of inflammasomes. Cell 157 (5): 1013–1022.
Pu, Q., Y. Zhao, Y. Sun, T. Huang, P. Lin, C. Zhou, S. Qin, B.B. Singh, and M. Wu. 2019. TRPC1 intensifies house dust mite-induced airway remodeling by facilitating epithelial-to-mesenchymal transition and STAT3/NF-kappaB signaling. FASEB J 33 (1): 1074–1085.
Sui, Y., L. Bian, Q. Ai, Y. Yao, M. Yu, H. Gao, A. Zhang, X. Fu, L. Zhong, and D. Lu. 2019. Gastrodin inhibits inflammasome through the STAT3 signal pathways in TNA2 astrocytes and reactive astrocytes in experimentally induced cerebral ischemia in rats. NeuroMolecular Med 21 (3): 275–286.
Jones, T.L., D.M. Neville, and A.J. Chauhan. 2018. Diagnosis and treatment of severe asthma: A phenotype-based approach. Clin Med (Lond) 18 (Suppl 2): s36–s40.
Zhang, H.P., L. Wang, Z. Wang, X.R. Xu, X.M. Zhou, G. Liu, L.Y. He, J. Wang, A. Hsu, W.M. Li, and G. Wang. 2018. Chinese herbal medicine formula for acute asthma: A multi-center, randomized, double-blind, proof-of-concept trial. Respir Med 140: 42–49.
Wang, M.H., C. Chen, M.L. Yeh, and J.G. Lin. 2019. Using traditional Chinese medicine to relieve asthma symptoms: A systematic review and meta-analysis. Am J Chin Med 47 (8): 1659–1674.
Shergis, J.L., L. Wu, A.L. Zhang, X. Guo, C. Lu, and C.C. Xue. 2016. Herbal medicine for adults with asthma: A systematic review. J Asthma 53 (6): 650–659.
Harrison, B.C., M.L. Bell, D.L. Allen, W.C. Byrnes, and L.A. Leinwand. 2002. Skeletal muscle adaptations in response to voluntary wheel running in myosin heavy chain null mice. J Appl Physiol (1985) 92 (1): 313–322.
Hirota, N., and J.G. Martin. 2013. Mechanisms of airway remodeling. Chest 144 (3): 1026–1032.
Vanaja, S.K., V.A. Rathinam, and K.A. Fitzgerald. 2015. Mechanisms of inflammasome activation: recent advances and novel insights. Trends Cell Biol 25 (5): 308–315.
Schroder, K., and J. Tschopp. 2010. The inflammasomes. Cell 140 (6): 821–832.
Theofani, E., M. Semitekolou, I. Morianos, K. Samitas, and G. Xanthou. 2019. Targeting NLRP3 inflammasome activation in severe asthma. J Clin Med 8 (10).
Shi, J., Y. Zhao, K. Wang, X. Shi, Y. Wang, H. Huang, Y. Zhuang, T. Cai, F. Wang, and F. Shao. 2015. Cleavage of GSDMD by inflammatory caspases determines pyroptotic cell death. Nature 526 (7575): 660–665.
Ding, J., and F. Shao. 2017. SnapShot: The noncanonical inflammasome. Cell 168 (3): 544–544 e541.
Pinkerton, J.W., R.Y. Kim, A.A.B. Robertson, J.A. Hirota, L.G. Wood, D.A. Knight, M.A. Cooper, L.A.J. O'Neill, J.C. Horvat, and P.M. Hansbro. 2017. Inflammasomes in the lung. Mol Immunol 86: 44–55.
Gao, J., S. Peng, X. Shan, G. Deng, L. Shen, J. Sun, C. Jiang, X. Yang, Z. Chang, X. Sun, F. Feng, L. Kong, Y. Gu, W. Guo, Q. Xu, and Y. Sun. 2019. Inhibition of AIM2 inflammasome-mediated pyroptosis by Andrographolide contributes to amelioration of radiation-induced lung inflammation and fibrosis. Cell Death Dis 10 (12): 957.
Cheng, K.T., S. Xiong, Z. Ye, Z. Hong, A. di, K.M. Tsang, X. Gao, S. An, M. Mittal, S.M. Vogel, E.A. Miao, J. Rehman, and A.B. Malik. 2017. Caspase-11-mediated endothelial pyroptosis underlies endotoxemia-induced lung injury. J Clin Invest 127 (11): 4124–4135.
Lamkanfi, M. 2011. Emerging inflammasome effector mechanisms. Nat Rev Immunol 11 (3): 213–220.
Kim, S.R., D.I. Kim, S.H. Kim, H. Lee, K.S. Lee, S.H. Cho, and Y.C. Lee. 2014. NLRP3 inflammasome activation by mitochondrial ROS in bronchial epithelial cells is required for allergic inflammation. Cell Death Dis 5: e1498.
Guo, M., F. An, H. Yu, X. Wei, M. Hong, and Y. Lu. 2017. Comparative effects of schisandrin A, B, and C on Propionibacterium acnes-induced, NLRP3 inflammasome activation-mediated IL-1beta secretion and pyroptosis. Biomed Pharmacother 96: 129–136.
Herbert, C., M. Sebesfi, Q.X. Zeng, B.G. Oliver, P.S. Foster, and R.K. Kumar. 2015. Using multiple online databases to help identify microRNAs regulating the airway epithelial cell response to a virus-like stimulus. Respirology 20 (8): 1206–1212.
Li, N., Y. He, and M.C. Li. 2015. Role of transient receptor potential canonical 1 in airway remodeling and effect of budesonide on its pulmonary expression in asthmatic guinea pigs. Nan Fang Yi Ke Da Xue Xue Bao 35 (10): 1374–1379.
Li, N., Y. He, G. Yang, Q. Yu, and M. Li. 2019. Role of TRPC1 channels in pressure-mediated activation of airway remodeling. Respir Res 20 (1): 91.
Chang, J., J. Gao, L. Lou, H. Chu, P. Li, T. Chen, and F. Gao. 2020. Xanthatin alleviates airway inflammation in asthmatic mice by regulating the STAT3/NF-kappaB signaling pathway. Respir Physiol Neurobiol 281: 103491.
Funding
This work was supported by the National Natural Science Foundation of China [grant number 81804144], the Shanghai Municipal Key Clinical Specialty [grant number shslczdzk04102], the Young Talents Clinical Ability Improvement Project of Longhua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine [grant number RC-2020-01-01], and the National TCM Clinical Research Base of Longhua Hospital affiliated to Shanghai University of Traditional Chinese Medicine [grant number LYTD-90].
Author information
Authors and Affiliations
Contributions
Xiufeng Chen: Conceptualization, Methodology. Zhen Xiao: Data curation, Writing- Original draft preparation. Zhiyan Jiang: Investigation. Yonghong Jiang: Supervision. Wen Li: Software. Mingjing Wang: Writing- Reviewing and Editing.
Corresponding authors
Ethics declarations
Ethics Approval and Consent to Participate
This study got the permission of the Ethical Committee of Longhua Hospital. All the animal experiments were implemented on the guide for the care and use of laboratory animals and on minimized animal number and the least pains.
Consent for Publication
Not applicable.
Competing Interests
The authors declare no competing interests.
Additional information
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Chen, X., Xiao, Z., Jiang, Z. et al. Schisandrin B Attenuates Airway Inflammation and Airway Remodeling in Asthma by Inhibiting NLRP3 Inflammasome Activation and Reducing Pyroptosis. Inflammation 44, 2217–2231 (2021). https://doi.org/10.1007/s10753-021-01494-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10753-021-01494-z